← 返回

血液系统恶性肿瘤和免疫学中 T 细胞治疗定量转化的基本原则

英文原题:Foundational Principles for the Quantitative Translation of T-Cell Therapeutics for Hematologic Malignancies and Immunology.

查看英文原题

Foundational Principles for the Quantitative Translation of T-Cell Therapeutics for Hematologic Malignancies and Immunology.

PubMed 2025/10/02(内容时间) Clin Pharmacol Ther Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞衔接抗体(TCE)和嵌合抗原受体(CAR)T细胞是精准医疗疗法,已革新血液系统恶性肿瘤的治疗。其肿瘤学领域的成功引发了将这一前景拓展至自身免疫性疾病等其他适应症的兴趣。本综述讨论机制建模的基础原则,旨在建立统一评估框架,支持跨治疗模式(CAR-T 与TCE)及跨适应症(肿瘤学与免疫学)的转化评估。该框架纳入各治疗模式的独特要素,如CAR-T 细胞动力学、TCE药代动力学及其与靶细胞形成复合物的过程;同时纳入不同适应症间共通的要素,如B细胞动力学和生物分布。我们阐述这种整合方法如何为免疫疗法的个体化、高效治疗策略提供循证决策依据。

展开英文摘要原文

T-cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR-T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders. This review discusses the foundational principles for mechanistic modeling to provide a unified assessment framework for cross-modality (i.

e. , CAR-T cells vs. TCEs) and cross-indication (i. e. , oncology vs. immunology) translation. This framework captures the unique elements of each modality, such as CAR-T cellular kinetics, TCE pharmacokinetics, and complex formation with target cells, as well as shared elements such as B-cell kinetics and biodistribution across indications.

We describe how this integrated approach can lead to informed decision making for more personalized and effective treatment strategies with these immune therapies.

论文信息

作者
Ashcroft P、McFann S、Ferguson A、Van De Vyver A、Gaudet S、Khera E、Schlender JF
单位
Biomedical Research, Novartis, Basel, Switzerland.Switzerland
文献类型
综述 · 非美国政府资助研究
期刊
Clinical pharmacology and therapeutics2026 Jan
原文标识
PubMed 41039855 · DOI 10.1002/cpt.70077